{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:24Z","timestamp":1786119264062,"version":"build-2736575974"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/mop.0b013e32832d1fef","type":"journal-article","created":{"date-parts":[[2009,7,20]],"date-time":"2009-07-20T03:24:08Z","timestamp":1248060248000},"page":"505-510","source":"Crossref","is-referenced-by-count":59,"title":["An update on Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in children"],"prefix":"10.1097","volume":"21","author":[{"given":"Mark Jean-Aan","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Kwang","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210206","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"R2-15-20210206","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R3-15-20210206","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00002018-200225130-00006","article-title":"Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience","volume":"25","author":"Forman","year":"2002","journal-title":"Drug Safety"},{"key":"R4-15-20210206","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/adc.83.4.347","article-title":"Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome","volume":"83","author":"Leaute-Labreze","year":"2000","journal-title":"Arch Dis Child"},{"key":"R5-15-20210206","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"key":"R6-15-20210206","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(96)90732-X","article-title":"Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra)","volume":"35","author":"Tay","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R7-15-20210206","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"R8-15-20210206","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R9-15-20210206","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R10-15-20210206","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R11-15-20210206","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"R12-15-20210206","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata","year":"1997","journal-title":"Cell"},{"key":"R13-15-20210206","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"R14-15-20210206","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.06.003","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases","volume":"52","author":"Abe","year":"2008","journal-title":"J Dermatol Sci"},{"key":"R15-15-20210206","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2340\/00015555-0074","article-title":"Diagnostic role of soluble Fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering diseases: a pilot study","volume":"86","author":"Lan","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"R16-15-20210206","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjo.2007.136796","article-title":"Association of Fas ligand gene polymorphism with Stevens-Johnson syndrome","volume":"92","author":"Ueta","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R17-15-20210206","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R18-15-20210206","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"R19-15-20210206","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator of disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"R20-15-20210206","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.4049\/jimmunol.174.9.5243","article-title":"Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator","volume":"174","author":"Deng","year":"2005","journal-title":"J Immunol"},{"key":"R21-15-20210206","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"R22-15-20210206","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R23-15-20210206","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.4049\/jimmunol.162.12.7140","article-title":"Crosstalk between keratinocytes and T lymphocytes via Fas\/Fas ligand interaction: modulation by cytokines","volume":"162","author":"Arnold","year":"1999","journal-title":"J Immunol"},{"key":"R24-15-20210206","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2133.2008.08524.x","article-title":"Expression of matrix metalloproteinases 2, 9 and 11 in erythema multiforme: immunohistochemical comparison with Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"158","author":"Caproni","year":"2008","journal-title":"Br J Dermatol"},{"key":"R25-15-20210206","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R26-15-20210206","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"R27-15-20210206","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity of illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"R28-15-20210206","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R29-15-20210206","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"R30-15-20210206","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1365-4632.2007.03277.x","article-title":"Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"46","author":"Fromowitz","year":"2007","journal-title":"Int J Dermatol"},{"key":"R31-15-20210206","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0884533608323434","article-title":"Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"23","author":"Mayes","year":"2008","journal-title":"Nutr Clin Pract"},{"key":"R32-15-20210206","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/BCR.0b013e31815f3658","article-title":"Treatment strategies in toxic epidermal necrolysis: where are we at?","volume":"29","author":"Abood","year":"2008","journal-title":"J Burn Care Res"},{"key":"R33-15-20210206","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jpedsurg.2006.08.043","article-title":"Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing","volume":"41","author":"Asz","year":"2006","journal-title":"J Pediatr Surg"},{"key":"R34-15-20210206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.burns.2006.12.008","article-title":"AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN)","volume":"34","author":"Huang","year":"2008","journal-title":"Burns"},{"key":"R35-15-20210206","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1525-1470.2008.00766.x","article-title":"Use of Suprathel dressing in a young infant with TEN","volume":"25","author":"Pfurtscheller","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"R36-15-20210206","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.burns.2007.06.008","article-title":"Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients","volume":"34","author":"Boorboor","year":"2008","journal-title":"Burns"},{"key":"R37-15-20210206","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","article-title":"Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series","volume":"62","author":"Yip","year":"2007","journal-title":"Allergy"},{"key":"R38-15-20210206","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.eye.6701653","article-title":"High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits","volume":"19","author":"Yip","year":"2005","journal-title":"Eye"},{"key":"R39-15-20210206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1542-0124(12)70273-2","article-title":"The ophthalmologic management of acute Stevens-Johnson syndrome","volume":"6","author":"Gregory","year":"2008","journal-title":"Ocul Surf"},{"key":"R40-15-20210206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R41-15-20210206","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"R42-15-20210206","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2332\/allergolint.O-07-483","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006","volume":"56","author":"Yamane","year":"2007","journal-title":"Allergol Int"},{"key":"R43-15-20210206","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"R44-15-20210206","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"R45-15-20210206","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.0906-6705.2006.00426.x","article-title":"Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis","volume":"15","author":"Parquet","year":"2006","journal-title":"Exp Dermatol"},{"key":"R46-15-20210206","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"R47-15-20210206","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00128071-200607060-00004","article-title":"Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"7","author":"Mittmann","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"R48-15-20210206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"R49-15-20210206","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"R50-15-20210206","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"R51-15-20210206","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2230.2005.01863.x","article-title":"The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"30","author":"Yeung","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"R52-15-20210206","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"R53-15-20210206","first-page":"2494","article-title":"Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome","volume":"27","author":"Morici","year":"2000","journal-title":"J Rheumatol"},{"key":"R54-15-20210206","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R55-15-20210206","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/0378-6323.18943","article-title":"Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study","volume":"71","author":"Mangla","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R56-15-20210206","first-page":"366","article-title":"Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children","volume":"37","author":"Lam","year":"2004","journal-title":"J Microbiol Immunol Infect"},{"key":"R58-15-20210206","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"},{"key":"R59-15-20210206","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1442-200X.2007.02439.x","article-title":"Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone","volume":"49","author":"Aihara","year":"2007","journal-title":"Pediatr Int"},{"key":"R60-15-20210206","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"R61-15-20210206","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-\u03b1 antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"R62-15-20210206","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-\u03b1 treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R63-15-20210206","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1744-9987.2008.00609.x","article-title":"Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan","volume":"12","author":"Yamada","year":"2008","journal-title":"Ther Apher Dial"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0b013e32832d1fef","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:55:44Z","timestamp":1786038944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008480-200908000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e32832d1fef","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}